The designer antibacterial peptide dimer, A3-APO and its monomeric in vivo metabolite exhibit remarkable efficacy in mouse models of multidrug-resistant Escherichia coli and Acinetobacter baumannii systemic infections. Due to the changing view of antimicrobial peptides as host-defense response modulators rather than direct bactericidal agents with special emphasis in cutaneous immune stimulating properties, we tested the efficacy of A3-APO and the monomer in a series of burn infection and acne vulgaris murine models. Upon single or repeated intramuscular or topical administration, the peptides reduced the bacterial counts and inflammation signs to baseline levels as well as dramatically improved wound appearance, regardless if they were able to kill the pathogens in vitro. Remarkably, even uninfected wounds healed better upon peptide treatment, likely due to recruitment of local macrophages and anti-inflammatory cytokine production. Most recently the monomer was incorporated into and delivered to the injury and infection sites with nanofibrous carrier polymers, providing a novel band-aid type medicated antimicrobial patch skin treatment option.